A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07377578 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

394

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Rocbrutinib
DRUG: Ibrutinib
DRUG: Acalabrutinib
DRUG: Zanubrutinib
DRUG: Orelabrutinib

Sponsor

Guangzhou Lupeng Pharmaceutical Company LTD.